Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 32 |
| Active Pipeline (Recruiting Now) | 10 (9) |
| Completed vs Stopped Early | 14 / 8 (25.0%) |
| Median Closed Actual Enrollment | 81 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 1 (1 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | 7 |
| Vanderbilt University Medical Center | Nashville, TN | 7 |
| Duke University Medical Center | Durham, NC | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06003387 | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus | Phase III | RECRUITING |
| NCT07080905 | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe He | Phase III | RECRUITING |
| NCT07094087 | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Ca | Phase III | RECRUITING |
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase II/III | RECRUITING |
| NCT07648264 | Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chime | Phase III | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the CSL Behring Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.